merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>The lack of correlation between amyloid plaque removal and clinical response in individual patients.</answer>

<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for potentially better treatments.</answer>

<question_number>3</question_number>
<answer>There's no correlation between amyloid plaque removal and clinical response in individual subjects.</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>The expectation that patients can stop Kisunla after their plaques are cleared.</answer>

<question_number>6</question_number>
<answer>It might discourage patients from participating in other clinical trials.</answer>

<question_number>7</question_number>
<answer>Kisunla is given monthly, while Leqembi is given every two weeks.</answer>

<question_number>8</question_number>
<answer>Amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels.</answer>